CAS NO: | 2245711-27-5 |
包装 | 价格(元) |
500 μg | 电议 |
1mg | 电议 |
5mg | 电议 |
Cas No. | 2245711-27-5 |
Canonical SMILES | OC(C[C@H](C[N+](C([2H])([2H])[2H])(C)C)OC(CCCCCCCCCCCCCCCCC)=O)=O.[Cl-] |
分子式 | C25H47D3NO4.Cl |
分子量 | 467.1 |
溶解度 | DMF: 20 mg/ml,DMSO: 14 mg/ml,Ethanol: 20 mg/ml |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Stearoyl-L-carnitine-d3(chloride) is intended for use as an internal standard for the quantification of stearoyl-L-carnitine by GC- or LC-MS. Stearoyl-L-carnitine is a naturally occurring long-chain acylcarnitine.1It inhibits sodium-dependent [3H]carnitine uptake in human proximal convoluted tubular (HPCT) cells by 52% when used at a concentration of 500 μM.2It also inhibits lecithin:cholesterol acyltransferase activity in rat, but not human, plasma when used at a concentration of 500 µM.3Plasma levels of stearoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.4,1 1.Reuter, S.E., Evans, A.M., Faull, R.J., et al.Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal diseaseAnn. Clin. Biochem.42(Pt 5)387-393(2005) 2.Huang, W., Shaikh, S.N., Ganapathy, M.E., et al.Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cellsBiochem. Pharmacol.58(8)1361-1370(1999) 3.Bell, F.P.Carnitine esters: Novel inhibitors of plasma lecithin: Cholesterol acyltransferase in experimental animals but not in man (Homo sapiens)Int. J. Biochem.15(2)133-136(1983) 4.Reuter, S.E., and Evans, A.M.Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activityJ. Intern. Med.270(1)76-84(2011) |